Message from the Chief
The Division of Hematology and Medical Oncology in The Tisch Cancer Institute represents one of the largest clinical and research divisions at Icahn School of Medicine. The division has a rich history of distinguished faculty and accomplishments in benign and malignant hematology, as well as solid tumor oncology.
Division faculty are responsible for significant contributions to understanding blood banking, the pathophysiology of polycythemia vera, the role of tissue factor in blood clotting, the factors driving cancers of the blood, the biology of liver cancer progression, and the abnormal signaling in breast and other cancer cells. They have also made critical contributions to the development of combination chemotherapy for solid tumors and leukemia, the development of differentiation therapy for cancer, the use of growth factors in the support of cancer patients, novel therapies for multiple myeloma, a new standard of care for induction chemotherapy for head and neck cancers, and the introduction of a new therapy for myelodysplasia.
The next era of our division will see significant growth in translational research and care for patients with cancer and hematological disorders. With the opening of the new clinical and research space in the Center for Science and Medicine in 2012, the division will be a key component of the outstanding multidisciplinary care provided in The Tisch Cancer Institute, as well as a driver of personalized cancer care.